A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered ATI-1123, a Liposomal Docetaxel Formulation, on an Every 3 Week Schedule, in Patients with Advanced Solid Tumors (Sponsor ID# ATI1123-101)
Available Locations
Mary Crowley Cancer Research Center - Medical City (Dallas, TX),
A Randomized Phase II Trial of Ridaforolimus (AP23573; MK-8669) Compared to Progestin or Chemotherapy in Female Adult Patients with Advanced Endometrial Carcinoma (Sponsor ID #AP23573-07-205)
Available Locations
Mary Crowley Cancer Research Center - Medical City (Dallas, TX),
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of IPI-493 Orally Administered to Patients with Advanced Malignancies (Sponsor ID# IPI-493-01)
Available Locations
Mary Crowley Cancer Research Center - Medical City (Dallas, TX),
A Phase 1b’, Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12 (INXN-3001) in Response to an Oral Activator Ligand Administered in Intra-Patient Escalating Doses in Patients With Unresectable Stage III C or IV Malignant Melanoma (Sponsor ID# RTS-M101B’)
Available Locations
Mary Crowley Cancer Research Center - Medical City (Dallas, TX),
Available Locations
Mary Crowley Cancer Research Center - Medical City (Dallas, TX),
Study: #05-27, An Open Label Phase I Dose Escalation Study Of E7080 Administered To Patients with Solid Tumors Or Lymphomas and Dose Confirmation Study in Patients with Melanoma(E7080-A001-102)
Available Locations
Mary Crowley Cancer Research Center - Baylor (Dallas, TX), Mary Crowley Cancer Research Center - Medical City (Dallas, TX),
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 Administered Orally Daily to Subjects with Solid Tumors or Lymphoma (XL147-001)
Available Locations
Mary Crowley Cancer Research Center - Medical City (Dallas, TX),
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm (Sponsor ID#20050236)
Available Locations
Mary Crowley Cancer Research Center - Baylor (Dallas, TX), Mary Crowley Cancer Research Center - Medical City (Dallas, TX),
An Open label single arm trial investigating zalutumumab, a Human Monoclonal Ante-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-based Chemotherapy (GEN205)
Available Locations
Warren Billhartz Cancer Center (Maryville, IL), , Mary Crowley Cancer Research Center - Baylor (Dallas, TX),
A Multi-Center Phase I Evaluation of the Doublet MHC Class I and II HER2/neu Peptide Vaccines (GP2 and AE37, respectively) in HLA-A2+ or HLA-A3+ Patients with Intermediate- to High-Risk Breast or Ovarian Cancer
Available Locations
Mary Crowley Cancer Research Center - Baylor (Dallas, TX),
